BeiGene, Hengrui Among China Firms Flexing New Oncology Muscle At ASCO
Executive Summary
In its bid to facilitate novel treatments for some of its most prevalent cancers, China is also poised to make a dent in the global oncology market through domestically originated agents, with the number of PD-1 and CAR-T therapies under clinical development already surpassing that in the US.